关注
Raygene Martier
Raygene Martier
Leiden university
在 vicotx.com 的电子邮件经过验证
标题
引用次数
引用次数
年份
Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease
J Miniarikova, I Zanella, A Huseinovic, T van der Zon, E Hanemaaijer, ...
Molecular Therapy-Nucleic Acids 5, 2016
1462016
AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease
J Miniarikova, V Zimmer, R Martier, CC Brouwers, C Pythoud, K Richetin, ...
Gene therapy 24 (10), 630-639, 2017
1052017
Activation-induced cytidine deaminase induces reproducible DNA breaks at many non-Ig Loci in activated B cells
O Staszewski, RE Baker, AJ Ucher, R Martier, J Stavnezer, JEJ Guikema
Molecular cell 41 (2), 232-242, 2011
1042011
Targeting RNA-mediated toxicity in C9orf72 ALS and/or FTD by RNAi-based gene therapy
R Martier, JM Liefhebber, A García-Osta, J Miniarikova, ...
Molecular Therapy-Nucleic Acids 16, 26-37, 2019
892019
Artificial microRNAs targeting C9orf72 can reduce accumulation of intra-nuclear transcripts in ALS and FTD patients
R Martier, JM Liefhebber, J Miniarikova, T van der Zon, J Snapper, ...
Molecular Therapy-Nucleic Acids 14, 593-608, 2019
672019
Gene therapy for neurodegenerative diseases: slowing down the ticking clock
R Martier, P Konstantinova
Frontiers in Neuroscience 14, 580179, 2020
582020
AAV5-miHTT lowers huntingtin mRNA and protein without off-target effects in patient-derived neuronal cultures and astrocytes
S Keskin, CC Brouwers, M Sogorb-Gonzalez, R Martier, JA Depla, ...
Molecular Therapy-Methods & Clinical Development 15, 275-284, 2019
532019
Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease
R Martier, M Sogorb-Gonzalez, J Stricker-Shaver, J Hübener-Schmid, ...
Molecular Therapy-Methods & Clinical Development 15, 343-358, 2019
522019
Transduction patterns in the CNS following various routes of AAV-5-mediated gene delivery
KL Pietersz, RM Martier, MS Baatje, JM Liefhebber, CC Brouwers, ...
Gene therapy 28 (7), 435-446, 2021
272021
Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver
P Maczuga, J Verheij, C Van Der Loos, R Van Logtenstein, G Hooijer, ...
Gene therapy 21 (1), 60-70, 2014
132014
In-depth characterization of a mifepristone-regulated expression system for AAV5-mediated gene therapy in the liver
JM Liefhebber, R Martier, T Van der Zon, S Keskin, A Huseinovic, ...
Molecular Therapy Methods & Clinical Development 13, 512-525, 2019
72019
Depla
S Keskin, CC Brouwers, M Sogorb Gonzalez, R Martier
Valles,.,… E ers, MM, 275-284, 2019
12019
Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3
MM Evers, PS Konstantinova, RM Martier
US Patent App. 17/319,546, 2022
2022
Rnai induced c9orf72 suppression for the treatment of als/ftd
RM Martier, PS Konstantinova
US Patent App. 17/196,531, 2021
2021
RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
MM Evers, PS Konstantinova, RM Martier
US Patent App. 16/684,028, 2020
2020
Therapeutic RNAi-based gene therapy for neurodegenerative disorders: slowing down the ticking clock
RM Martier
Leiden University, 2020
2020
Baat e, MS, Liefhebber
KL Pietersz, RM Martier
M., Brouwers, CC, Pouw, S. M.,… Blits, B, 435-446, 2020
2020
A novel AAV-based miQURE gene therapy for SCA3
L Toonen, RJ Nobre, ME Haas, J Stricker-Shaver, J Hübener-Schmid, ...
HUMAN GENE THERAPY 30 (11), A91-A92, 2019
2019
Development of an AAV-based microRNA gene therapy for treating spinocerebellar ataxia type 3
M Evers, R Martier, J Stricker-Shaver, J Hubener-Schmid, S Keskin, ...
NEUROLOGY 93 (5), E531-E531, 2019
2019
I06 Efficacy and safety of AAV5-MIHTT in hd patient-derived neurons
M Evers, S Keskin, C Brouwers, M Sogorb-Gonzalez, R Martier, J Depla, ...
Journal of Neurology, Neurosurgery & Psychiatry 89 (Suppl 1), A90-A90, 2018
2018
系统目前无法执行此操作,请稍后再试。
文章 1–20